Anne Le Assistant Professor Johns Hopkins University School of Medicine Assessing the Effects of the Tumor's Microenvironment on the Sensitivity to Metabolic Inhibitors with a Dual Fluorescent Protein Reporter Talk Time: 30 January AM Read more...
Jason Locasale Assistant Professor, Division of Nutritional Sciences Cornell University The consequences of enhanced glucose metabolism Talk time: 31 January AM Read more...
Harold Selick Chief Executive Officer Threshold Pharmaceuticals Case Study: Targeting Tumor Hypoxia with TH-302 as Anti-Cancer Therapy Talk time: 31 January AM Read more...
Paul Bingham Vice President, Research Cornerstone Pharmaceuticals Case Study: First-in-class drug, CPI-613 simultaneously Targets Multiple Mitochondrial Metabolic Regulatory Processes in Tumor Cells Talk time: 31 January AM Read more...
Alec Kimmelman Assistant Professor, Radiation Oncology Dana Farber Cancer Institute Targeting Pancreatic Cancer using Autophagy and Metabolism Talk time: 31 January AM Read more...
Beat Nyfeler Research Investigator Novartis Institutes for BioMedical Research Successfully Identifying Targets within Cancer Metabolism Talk time: 30 January PM Read more...
Genshi Zhao Research Advisor Eli Lilly and Company Using Sophisticated Technology to Study Cellular Metabolism in Cancer Talk time: 30 January AM Read more...
Michael Lisanti Director Breakthrough Breast Cancer Research Unit, The University of Manchester Therapeutic Opportunities for the Exploiting the “Reverse Warburg Effect” and “Two-Compartment” Cancer Metabolism Talk time: 30 January AM Read more...
Valeria Fantin Vice President, Tumor Cell Biology Pfizer Predicting the Necessity to Block Multiple Pathways to Overcome Potential Redundancies and By-Pass Mechanisms Talk time: 30 January PM Read more...
Gilles Tapoisky CSO Advanced Cancer Therapeutics Preclinical Characterization of Antagonists of 6-Phosphofructo-2-Kinase that Suppress Glucose Metabolism and Tumor Growth Talk time: 31 January PM Read more...
Lars Ährlund-Richter CSO Kancera Attacking PFKFB3 Using a Structure-Based Design Approach Talk time: 31 January PM Read more...
Peter Dragovich Principal Scientist Genentech Case Study: Design of Optimized Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Talk time: 30 January PM Read more...
Anke Klippel-Giese Senior Director, Oncology Pfizer Panel Discussion: Why Invest in Cancer Metabolism? Talk time: 30 January PM Read more...
Byron DeLaBarre Associate Director, Biochemistry Agios Case Study: Structure-Function Studies of a Glutaminase-Inhibitor Complex Talk time: 31 January PM Read more...
Francis Kern Senior Director, External Scientific Affairs Daiichi Sankyo Panel Discussion: Why Invest in Cancer Metabolism? Talk time: 30 January PM Read more...
Edward Driggers Senior Director, Cell Metabolism Agios Using High Throughput Metabolomics, Flux Analysis, and Target Discovery to Target Novel Pathways in Cancer Talk time: 30 January PM Read more...
Katharine Yen Director of Biology, Agios pharmeceuticals Agios Case Study: IDH Mutations and Tumorigenecity Talk time: 30 January PM Read more...
Anders Åberg CEO/CSO and founder Sprint Bioscience Establishing a project portfolio within tumor metabolism boosted by a fragment-based approach Read more...
Andrea Eckhart Associate Director, US Pharma/Biotech Metabolon Applying Metabolytics to Achieve R&D Efficiency Talk time: 30 January AM Read more...
Hajo Schiewe, Ph.D. Senior Manager Business Development North America Metanomics Health - a BASF Company Hajo is currently responsible for science-based business development in the western part of the US. He received his PhD in bio-organic chemistry from the University of Goettingen, Germany. Since then he held positions of increasing responsibility at the interface between science and business in innovative biotechnology companies including Director of Scientific Development and Executive Vice President Business Development.